Browsing by Author "Birlik, M."
Now showing 1 - 5 of 5
- Results Per Page
- Sort Options
Article Citation - WoS: 2Citation - Scopus: 2Does Arterial Stiffness Predict Mortality in Patients With Scleroderma: a Long-Term Follow-Up Study(Verduci Editore s.r.l, 2023) Çolak, A.; Özpelit, Mehmet Emre; Birlik, M.; Özpelit, E.OBJECTIVE: Subclinical macrovascular impairment, which has been evaluated with various arterial stiffness (AS) parameters, has been defined in patients with systemic sclerosis (SSc). However, studies investigating the relationship between AS and clinical endpoints in SSc are lacking. This study aims to determine the prognostic value of AS parameters to predict all-cause mortality in SSc patients. PATIENTS AND METHODS: AS parameters [carotid-radial pulse wave velocity (PWV) and augmentation index (AIx)] were assessed via applanation tonometry. The prognostic value of these parameters was quantified in patients with SSc (n=60) without pulmonary arterial hypertension (PAH) and obvious cardiac involvement against survival. RESULTS: The overall median follow-up time was 10.3 years, and a 29.4% (n=20) mortality was observed. Four significant predictors of mortality were observed: lung involvement (HR 2.608, p=0.04), the lower level of predicted carbon monoxide diffusing capacity (HR 0.978, p=0.03), lower level of estimated glomerular filtration rate (HR 0.979, p=0.04), and elevated serum C reactive protein (CRP) levels (HR 1.066, p<0.001). Among these variables, elevated CRP was found to be an independent predictor of all-cause mortality. AS parameters were not associated with all-cause mortality (HR 1.014, p=0.6 for AIx and HR 0.737, p=0.19 for PWV, respectively). CONCLUSIONS: Long-term data failed to demonstrate the prognostic value of AS parameters in predicting all-cause mortality in SSc patients. The exact mechanisms of cardiovascular (CV) mortality in SSc patients deemed to be atherosclerotic in origin needs to be determined in large-scale studies. © 2023 Verduci Editore s.r.l. All rights reserved.Conference Object Fibrosis Modulation in Scleroderma by Epigallocatechin-3(Wiley, 2017) Kocak, A.; Harmanci, D.; Birlik, M.; Sarioglu, S.; Yilmaz, O.; Cavdar, Z.; Akdoğan, Gül[Abstract Not Available]Conference Object Molecular Mechanisms Mediating Antioxidant Effect of Epigallocatechin-3 in Experimental Scleroderma Model(Bmj Publishing Group, 2018) Kocak, A.; Harmanci, D.; Birlik, M.; Guner, G.[Abstract Not Available]Conference Object Protective Effects of Epigallocatechin 3 Gallate on Fibrosis in Scleroderma Model(Bmj Publishing Group, 2017) Kocak, A.; Harmanci, D.; Birlik, M.; Sarioglu, S.; Akdoğan, Gül[Abstract Not Available]Conference Object VITAMIN D AND VITAMIN D RECEPTOR IN PATIENTS WITH SCLERODERMA SUBTYPES(Bmj Publishing Group, 2018) Kocak, A.; Harmanci, D.; Birlik, M.; Guner, G.[Abstract Not Available]